Navigation Links
Scientists find new way to induce programmed cell death, or apoptosis
Date:7/17/2012

Researchers from the Hebrew University of Jerusalem and the Weizmann Institute of Science have developed a technique to cause apoptosis, or programmed cell death, that could lead to new approaches to treating cancer.

Apoptosis is an essential defense mechanism against the spread of abnormal cells such as cancer. It is a complex process that occurs through networks of proteins that interact with each other. Cancer cells usually avoid this process due to mutations in the genes that encode the relevant proteins. The result is that the cancer cells survive and take over while healthy cells die.

The research, by graduate student Chen Hener-Katz at the Hebrew University, involved collaboration between Prof. Assaf Friedler of the Hebrew University's Institute of Chemistry and Prof. Atan Gross of the Weizmann Institute's Department of Biological Regulation. It was published in the Journal of Biological Chemistry under the title "Molecular Basis of the Interaction between Proapoptotic Truncated BID (tBID) Protein and Mitochondrial Carrier Homologue 2 (MTCH2) Protein."

The study examined the interaction between two important proteins involved in cell death: mitochondrial carrier homologue 2 (MTCH2), which was discovered in the lab of Prof. Gross, and truncated BID (tBID), which are both involved in the apoptotic process. The researchers found the regions in the two proteins that are responsible for binding to each other, a critical step in initiating apoptosis. Following their discovery, the researchers developed short synthetic protein fragments, or peptides, that mimicked the areas on the proteins that bind to each other, and by doing so inhibited this binding. In lab experiments conducted on cell cultures, this resulted in the death of cancer cells of human origin.

"These protein segments could be the basis of future anti-cancer therapies in cases where the mechanism of natural cell death is not working properly," said Prof. Friedler. "We have just begun to uncover the hidden potential in the interaction between these proteins. This is an important potential target for the development of anticancer drugs that will stimulate apoptosis by interfering with its regulation. "

Prof. Friedler is the head of the school of chemistry at the Hebrew University. His major research interests are using peptides to study protein-protein interactions in health and disease, and developing peptides as drug leads that modulate these interactions, specifically in relation to HIV and cancer. Prof. Friedler won the prestigious starting grant from the ERC (European Research Council) as well as the outstanding young scientist prize by the Israeli Chemical Society. His research was supported by a grant from the Israel Ministry of Health and by a starting grant from the European Research Council.


'/>"/>

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-81641
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. New York Stem Cell Foundation scientists featured for new model of Alzheimers disease
2. SIgN scientists discover dendritic cells key to activating human immune responses
3. UW scientists discover why human body cannot fight HIV infection
4. Scientists Pinpoint Antibody That May Be Specific to MS Patients
5. Scientists first to see trafficking of immune cells in beating heart
6. Scientists develop new strategy to overcome drug-resistant childhood cancer
7. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
8. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
9. Scientists develop mouse model that could lead to new therapies for liver cancer
10. Scientists Use Stem Cells to Mimic Huntingtons Disease
11. Scientists identify gene linked to facial, skull and cognitive impairment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... to Thrive , Well-meaning studies such as the Fordham Institute’s High Stakes ... serve top students, such as including gifted or high-achieving students as a subgroup ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate ... Global Climate Change and Your Health on Voice America, once again welcomed one ...
(Date:1/24/2017)... ... ... A yellow fever outbreak in Brazil has infected over 100 people and claimed ... contact with infected mosquitos. The outbreak has sparked increased concern about the virus and ... multiple health organizations, the best way to prevent yellow fever is through vaccination. For ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. ... authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, they ...
(Date:1/24/2017)... ... , ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic ... Christians. “Mysteries Revealed On Speaking In Tongues” is the creation of published author, Tina ... located in Michigan. , “We need to partner with Jesus and be the ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future has ... Market for Wound Closure Device is growing rapidly and expected to continue ... ... at a CAGR of 5% from 2013 to 2019 and reaching a ... of the forecasted period, 2016-2022 Global Wound Closure Device Market ...
(Date:1/24/2017)... Nev. , Jan. 24, 2017  The ... that specializes in high-value orthopaedic implants, announced the ... today. The OIC Tibial Nail ... tibia. Strategically placed proximal and distal screw holes ... hole that allows dynamization.  The nail is available ...
(Date:1/24/2017)... 2017 Trifecta Clinical , a leading ... Rick Ward to Vice President of Commercial ... also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he was ... business development positions within the healthcare industry throughout his ...
Breaking Medicine Technology: